KRAS and non-small cell lung carcinoma: RNAi-mediated knockdown of oncogenic mutant K-Ras blocks cell survival and growth in a range of pancreatic and non-small-cell lung cancers (NSCLC), which provides the rationale that blocking oncogenic K-Ras activity is a valid approach to treat K-Ras-dependent cancers.